Li / Johnson / Sliskovic Contemporary Drug Synthesis

1. Auflage 2004
ISBN: 978-0-471-68673-6
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 240 Seiten, E-Book

Reihe: Wiley Series on Drug Synthesis

An integrated and insightful look at successful drug synthesis intoday's drug discovery market
The pharmaceutical industry is unquestionably vibrant today,with drug synthesis making a vital contribution. Whether in theearly developmental stages of identifying and optimizing a lead, orthe latter stages of process development and cost-effectivescale-up, the ability to design elegant and economical syntheticroutes is often a major factor in the eventual viability andcommercial success of a drug.
Contemporary Drug Synthesis examines how leadingresearchers and manufacturers have integrated chemistry, biology,pharmacokinetics, and a host of other disciplines in the creationand development of leading drugs.
Authored by four of the pharmaceutical industry's most respectedscientists, this timely volume:
* Focuses on the processes that resulted in high-profile drugsincluding Lipitor, Celebrex, Viagra, Gleevec, Nexium, Claritin, andover a dozen others
* Provides an in-depth introduction to each drug, followed by adetailed account of its synthesis
* Organizes the drugs into fourteen therapeutic areas for clarityand ease of use
Process chemists provide an essential bridge between chemistry andthe marketplace, creating scientifically practical drug processeswhile never losing sight of the commercial viability of thoseprocesses. Contemporary Drug Synthesis meets the needs of agrowing community of researchers in pharmaceutical research anddevelopment, and is both a useful guide for practicingpharmaceutical scientists and an excellent text for medicinal andorganic chemistry students.

Autoren/Hrsg.

Li, Jie Jack

Johnson, Douglas S.

Sliskovic, Drago R.

Roth, Bruce

Inhaltsverzeichnis

Preface v
Trade Names and Their Corresponding USANs xi
Acronyms and Abbreviations xiii
Chapter 1. Antithrombotics: Ticlopidine (Ticlid) and Clopidogrel (Plavix) 1
Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex) and Rofecoxib (Vioxx) 11
Chapter 3. H¯+/K¯+ -ATPase Inhibitors: Esomeprazole (Nexium) 21
Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatnib (Gleevec) and Gefitinib (Iressa) 29
Chapter 5. Non-sedating Antihistamines 39
Chapter 6. Cosmeceuticals: Istretinoin (Accutane), Tazarotene (Tazorac), Minoxidil (Rogaine), and Finasteride (Propecia) 55
Chapter 7. Antibacterials: Ciprofloxacin (Cipro) and Linezolid (Zyvox) 75
Chapter 8. Atypical Antupsychotics 89
Chapter 9. Atovastatin Calcium (Lipitor) 113
Chapter 10. Antidepressants 125
Chapter 11. Anti-obesity: Orlistat (Xenical) 149
Chapter 12. Triptans for Migrane 161
Chapter 13. PDE 5 Inhibitors for Erectile Dysfunction: Sildenafil (Viagra), Vardenafil (Levitra), and Tadalafil (Cialis) 189
Chapter 14. Antiasthmatics 201
Index 214

Über Autor(innen)

JIE-JACK LI, PhD, DOUGLAS S. JOHNSON, PhD, DRAGO R. SLISKOVIC, PhD, AND BRUCE D. ROTH, PhD, are all members of Pfizer Global Research and Development, and are among the most prominent scientists working in drug discovery today.